<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939509</url>
  </required_header>
  <id_info>
    <org_study_id>1445</org_study_id>
    <nct_id>NCT01939509</nct_id>
  </id_info>
  <brief_title>Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol</brief_title>
  <acronym>CHAB</acronym>
  <official_title>Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory
      could improve the peripheral arterial perfusion and could have a greater antihypertensive
      effect. At the same time, this could carry objectifiable improvements in the vascular tree,
      such as the level of arterial stiffness.

      This study attempts to mark the hemodynamic differences in the same individual with
      hypertension and metabolic syndrome who will be exposed to both drugs at different moments.
      Parameters will be objectified with impedance cardiography, pulse wave velocity and central
      blood pressure assessment before and after taking each one of the drugs. The results will be
      compared to the baseline data and between themselves.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central blood pressure</measure>
    <time_frame>two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>peripheral resistance</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)</description>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <arm_group_label>Atenolol-Bisoprolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension

          -  Metabolic syndrome

        Exclusion Criteria:

          -  Severe hypertension &gt;180/110

          -  Secondary hypertension

          -  Contraindication for betablockers

          -  Prior treatment with betablockers (up to one month before inclusion)

          -  History of neoplastic disease

          -  Patients that do not sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel D Waisman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>c118ach</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Lucas Aparicio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

